GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd, entered into an exclusive distribution agreement with This Works Products Limited for the distribution and sale of the joint venture’s functional mushroom brand, GOODMIND™, in the United Kingdom and Europe.

This Works is one of the leading skincare and wellbeing companies in the United Kingdom and in line with the exclusive distribution agreement, This Works will commence sales of the GOODMIND™ functional mushroom capsules through the This Works website (www.thisworks.com) in November 2022. In Q1 2023, the GOODMIND™ sachets will also be made available for sale through the This Works website and at select retail stores.

“We believe there is significant growth in the functional mushroom space and are excited to leverage our branding and marketing expertise alongside the technical strength of Psyence, their world class scientific team and This Works to launch GOODMIND™ in what we believe are strategic markets for our products.” says Warren Schewitz, Founder and Chief Executive Officer of Goodleaf.

“At This Works, we look at health holistically. We know that when it comes to how our skin performs, there are many contributing factors, including quality of sleep, nutrition, and physical exertion. We champion products that work hand-in-hand with our skin, body and wellness solutions and GOODMIND’s™ premium range of functional mushroom formulas are a great example of that,” says Dr Anna Persaud, CEO This Works.

The GOODMIND™ functional mushroom formulas harness the power of adaptogens; non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits.  GOODMIND™ products, in capsule format and sachets, are available for sale in South Africa via www.foragoodmind.com and now in the United Kingdom and Europe through www.thisworks.com.  

The Company further announces that Gavin Basserabie has tendered his resignation from the board with immediate effect, however as a founder, he retains a strong interest in the Company.  The Company thanks Gavin for his service to the board.

The board of directors of the Company consists of Jody Aufrichtig, Dr. Neil Maresky, Alan Friedman and Marvin Singer. 

Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.    

Informed by nature and guided by science, we built and operate one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Southern Africa. Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development.  We work to develop advanced natural psilocybin products for clinical research and development.

Our key divisions, Psyence Production, Psyence Therapeutics and Psyence Function, anchor an international collaboration, with operations in Canada, the United Kingdom, Southern Africa, and a presence in the United States and Australia